ISLAND PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.066 AUD | -1.49% |
|
-2.94% | -30.53% |
| May. 08 | Island Pharmaceuticals Reallocates Grant Funding to Dengue Fever Trial; Shares Rally 13% | MT |
| Apr. 16 | Island Pharmaceuticals Reports Positive Data from Dose Study of Dengue Medication | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.56M 11.33M |
|---|---|---|---|---|---|
| Net income 2024 * | -2M -3M | Net income 2025 * | -2M -3M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 600K 899K | Net cash position 2025 * | 3.1M 4.65M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.2
x | P/E ratio 2025 * |
-4.13
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 41.26% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.49% | ||
| 1 week | -2.94% | ||
| Current month | -1.49% | ||
| 1 month | +17.86% | ||
| 3 months | -9.59% | ||
| 6 months | -9.59% | ||
| Current year | -30.53% |
1 week
0.07
0.08
1 month
0.060.08
Current year
0.050.10
1 year
0.050.13
3 years
0.050.39
5 years
0.050.67
10 years
0.050.67
| Managers | Title | Age | Since |
|---|---|---|---|
David Foster
FOU | Founder | - | 20-05-24 |
Jane Lowe
IRC | Investor Relations Contact | - | - |
Stephanie Vipond
SEC | Corporate Secretary | - | Nov. 30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Al Hansen
BRD | Director/Board Member | 69 | 20-09-30 |
Paul MacLeman
CHM | Chairman | 58 | 20-05-24 |
David Brookes
BRD | Director/Board Member | 63 | 20-09-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-02 | 0.066 | -1.49% | 76 588 |
| 24-05-31 | 0.067 | -11.84% | 56,542 |
| 24-05-30 | 0.076 | -5.00% | 457,988 |
| 24-05-29 | 0.08 | +6.67% | 60,000 |
| 24-05-28 | 0.075 | -2.60% | 347,917 |
Delayed Quote Australian S.E., June 02, 2024 at 11:47 pm EDT
More quotes
Island Pharmaceuticals Limited is an Australia-based drug repurposing company, focused on areas of need for antiviral therapeutics to address infectious diseases. The Company's lead asset is ISLA-101, a drug, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. ISLA-101 has been shown to have activity against all four strains of dengue virus as well as other flaviviruses such as Zika virus, West Nile virus, and Yellow Fever virus, as well as Chikungunya virus. The Company operates a single segment, being research and development activities principally in the geographic regions of Australia and the United States. Its subsidiary is Isla Pharmaceuticals Inc.
Calendar
2024-08-21
- Q4 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -30.53% | 5.1M | |
| +14.23% | 118B | |
| +12.94% | 106B | |
| -3.46% | 24.28B | |
| +1.14% | 21.96B | |
| -9.35% | 18.16B | |
| -42.28% | 16.37B | |
| -18.01% | 15.56B | |
| +4.34% | 13.63B | |
| +27.59% | 12.27B |
- Stock Market
- Equities
- ILA Stock
